Suppr超能文献

新冠疫情对哮喘急性加重的影响:基于英国一个全国性基层医疗数据库中50多万患者的回顾性队列研究

Impact of COVID-19 pandemic on asthma exacerbations: Retrospective cohort study of over 500,000 patients in a national English primary care database.

作者信息

Shah Syed Ahmar, Quint Jennifer K, Sheikh Aziz

机构信息

Asthma UK Centre for Applied Research, Usher Institute, The University of Edinburgh, Edinburgh, UK.

National Heart & Lung Institute, Imperial College London, UK.

出版信息

Lancet Reg Health Eur. 2022 Aug;19:100428. doi: 10.1016/j.lanepe.2022.100428. Epub 2022 Jun 15.

Abstract

BACKGROUND

Several countries reported a substantial reduction in asthma exacerbations associated with COVID-19 pandemic-related restrictions. However, it is not known if these early reported declines were short-term and if these have rebounded to pre-pandemic levels following easing of lockdown restrictions.

METHODS

We undertook a retrospective, cohort study of all asthma patients in a national primary care database of almost 10 million patients, Optimum Patient Care Database (OPCRD), identified from January 1, 2010, to December 31, 2015, using a previously validated algorithm. We subsequently followed the identified cohort of asthma patients from January 1, 2016, to October 3, 2021, and identified every asthma exacerbation episode with a validated algorithm. To quantify any pandemic-related change in exacerbations, we created a control time-series (mean of 2016-2019) and then compared the change in exacerbation rate in 2020-2021 over quarterly periods when compared with the control period (the pre-pandemic period). We undertook overall and stratified analyses by age group, sex, and English region.

FINDINGS

We identified 100,362 asthma patients (502,669 patient-years) from across England who experienced at least one exacerbation episode (298,390 exacerbation episodes during the entire follow-up). Except for the first quarter of 2020, the exacerbation rates were substantially lower (>25%) during all quarters in 2020-2021 when compared with the rates during 2016-2019 (39.7% (95% Confidence Interval (CI): 34.6, 44.9) in quarter-2, 2020; 46.5% (95%CI: 36.7, 56.4) in quarter-3, 2020; 56.3% (95%CI: 48.7, 63.9) in quarter-4, 2020; 63.2% (95%CI: 53.9, 72.5) in quarter-1, 2021; 57.7% (95%CI: 52.9, 62.4) in quarter-2, 2021; 53.3% (95%CI: 43.8, 62.8) in quarter-3, 2021).

INTERPRETATION

There was a substantial and persistent reduction in asthma exacerbations across England over the first 18 months after the first lockdown. This is unlikely to be adequately explained by changes in health-seeking behaviour, pandemic-related healthcare service disruption, or any air-quality improvements.

FUNDING

Asthma UK, Health Data Research UK (HDR UK), Medical Research Council (MRC), National Institute for Health Research (NIHR).

摘要

背景

多个国家报告称,与新冠疫情相关的限制措施使哮喘急性发作显著减少。然而,尚不清楚这些早期报告的下降是否为短期现象,以及在封锁限制放宽后是否已反弹至疫情前水平。

方法

我们对一个拥有近1000万患者的全国初级医疗数据库——最佳患者护理数据库(OPCRD)中2010年1月1日至2015年12月31日期间的所有哮喘患者进行了一项回顾性队列研究,采用先前验证过的算法进行识别。随后,我们对2016年1月1日至2021年10月3日期间确定的哮喘患者队列进行随访,并使用经过验证的算法识别每一次哮喘急性发作事件。为了量化与疫情相关的急性发作变化,我们创建了一个对照时间序列(2016 - 2019年的平均值),然后将2020 - 2021年各季度的急性发作率变化与对照期(疫情前时期)进行比较。我们按年龄组、性别和英格兰地区进行了总体和分层分析。

结果

我们从英格兰各地识别出100362名哮喘患者(502669患者年),他们经历了至少一次急性发作事件(整个随访期间有298390次急性发作事件)。与2016 - 2019年期间相比,除2020年第一季度外,2020 - 2021年所有季度的急性发作率均大幅降低(超过25%)(2020年第二季度为39.7%(95%置信区间(CI):34.6,44.9);2020年第三季度为46.5%(95%CI:36.7,56.4);2020年第四季度为56.3%(95%CI:48.7,63.9);2021年第一季度为63.2%(95%CI:53.9,72.5);2021年第二季度为57.7%(95%CI:,52.9,62.4);2021年第三季度为53.3%(95%CI:43.8,62.8))。

解读

在首次封锁后的前18个月里,英格兰各地哮喘急性发作显著且持续减少。这不太可能通过就医行为的变化、与疫情相关的医疗服务中断或空气质量的任何改善来充分解释。

资金来源

英国哮喘协会、英国健康数据研究(HDR UK)、医学研究理事会(MRC)、国家卫生研究院(NIHR)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6a9/9417906/e9e9f1e8be7b/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验